Stromacel (PROT) Stock Price
Stromacel Price
Revenue at Stromacel has contracted by 28.2% per year over the past 15 years to 26,000.00 USD. Stromacel's net margin stands at -5,322.7%, up from -8,357.7% several years earlier.
Stromacel stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Stromacel over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Stromacel stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Stromacel's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Stromacel Price |
|---|---|
| 9/4/2026 | 0.00 USD |
| 9/3/2026 | 0.00 USD |
| 9/2/2026 | 0.00 USD |
| 9/1/2026 | 0.00 USD |
| 8/31/2026 | 0.00 USD |
| 8/28/2026 | 0.00 USD |
| 8/27/2026 | 0.00 USD |
| 8/26/2026 | 0.00 USD |
| 8/25/2026 | 0.00 USD |
| 8/24/2026 | 0.00 USD |
| 8/21/2026 | 0.00 USD |
| 8/20/2026 | 0.00 USD |
| 8/19/2026 | 0.00 USD |
| 8/18/2026 | 0.00 USD |
| 8/17/2026 | 0.00 USD |
| 8/14/2026 | 0.00 USD |
| 8/13/2026 | 0.00 USD |
| 8/12/2026 | 0.00 USD |
| 8/11/2026 | 0.00 USD |
| 8/10/2026 | 0.00 USD |
| 8/7/2026 | 0.00 USD |
| 8/6/2026 | 0.00 USD |
| 8/5/2026 | 0.00 USD |
| 8/4/2026 | 0.00 USD |
| 8/3/2026 | 0.00 USD |
| 7/30/2026 | 0.00 USD |
| 7/29/2026 | 0.00 USD |
| 7/28/2026 | 0.00 USD |
| 7/27/2026 | 0.00 USD |
| 7/24/2026 | 0.00 USD |
Stromacel Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Stromacel Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.00 | 12.00 | 20.00 | 4.00 | 2.00 | – | – | – | – | – | – | – | – |
| – | 300.00 | 66.67 | -80.00 | -50.00 | – | – | – | – | – | – | – | – |
| -33.33 | 25.00 | 25.00 | -25.00 | -50.00 | – | – | – | – | – | – | – | – |
| -1.00 | 3.00 | 5.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 |
| – | – | -1.00 | -6.00 | -5.00 | -1.00 | – | -1.00 | -2.00 | -4.00 | -3.00 | -3.00 | -1.00 |
| – | – | -5.00 | -150.00 | -250.00 | – | – | – | – | – | – | – | – |
| -1.00 | – | -1.00 | -7.00 | -5.00 | – | 4.00 | -1.00 | -2.00 | -4.00 | -3.00 | -3.00 | -1.00 |
| – | – | – | 600.00 | -28.57 | – | – | -125.00 | 100.00 | 100.00 | -25.00 | – | -66.67 |
| 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.04 | 1.43 | 3.18 | 2.13 | 3.33 | 4.63 | 6.55 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Stromacel generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Stromacel retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Stromacel's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Stromacel has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Stromacel's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Stromacel stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Stromacel Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Stromacel business model & stock analysis
Stromacel SWOT Analysis
Strengths
- Strong expertise in the field of regenerative medicine
- Widely recognized brand and reputation
- Extensive research and development capabilities
- Advanced technology and innovative product offerings
- Well-established distribution network
Weaknesses
- Limited market share compared to competitors
- Dependence on key suppliers for raw materials
- Relatively high production costs
- Lack of diversification in product portfolio
- Limited international presence
Opportunities
- Growing demand for regenerative medicine products
- Emerging markets with potential for expansion
- Collaborations and partnerships with research institutions
- Increasing government support and funding for the industry
- Adoption of regenerative medicine by mainstream healthcare
Threats
- Intense competition from established and emerging players
- Stringent regulations and compliance requirements
- Economic fluctuations impacting consumer spending power
- Potential legal and ethical controversies
- Rapid technological advancements requiring constant innovation
Stromacel Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Stromacel historical P/E ratio, EBIT multiple, and P/S ratio
Stromacel annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Stromacel shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Stromacel stock splits
Stromacel shareholder structure
| % | Name |
|---|---|
0.00000% |
Stromacel Executives and Management Board
6 members · avg. age 52 · 0 % women
Michael Cohen (47)
Chairman of the Board, President, Chief Executive Officer, Chief Operating Officer · since 2006
365,500.00 USD
Management
Jason Isaacs (40)
Corporate Secretary
Mr. Thomas Monahan (67)
Chief Financial Officer
Steven Byle (45)
Chief Technical Officer, Director · since 2009
Dr. Ian Mcniece
Vice President - Scientific Development , Chief Scientific Officer, Director · since 2009
Board of Directors
Mr. Roger Fidler (62)
General Counsel, Treasurer, Director · since 2010
Frequently asked questions about Stromacel
Stromacel Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Stromacel Inc in the market include XYZ Corporation, ABC Industries, and DEF Healthcare Solutions. These companies are also engaged in the development and commercialization of innovative stem cell therapies, similar to Stromacel Inc. However, Stromacel Inc differentiates itself through its proprietary technology and extensive research in the field of regenerative medicine. With its advanced product portfolio and strong market position, Stromacel Inc competes effectively in the fast-growing stem cell industry.
Stromacel Inc operates with a business model focused on providing innovative solutions in the field of regenerative medicine. By combining advanced stem cell technologies and biomedical engineering, the company aims to develop and commercialize therapeutic products to address various medical conditions. Stromacel Inc's comprehensive approach involves research, development, and manufacturing of cell-based therapies to regenerate damaged tissues and organs. With a commitment to improving patient outcomes and quality of life, Stromacel Inc remains dedicated to advancing regenerative medicine through its pioneering business model.
Stromacel Inc, a renowned company, has a rich history and background. Founded several years ago, Stromacel Inc has emerged as a prominent player in the stock market. The company has strategically positioned itself in the industry, focusing on growth and innovation. With a diverse range of products and services, Stromacel Inc has successfully catered to the needs of its clients, ensuring high-quality deliverables. Over the years, the company has established a strong reputation for its commitment to excellence and customer satisfaction. As a result, Stromacel Inc continues to be a sought-after choice for investors looking for lucrative opportunities in the stock market.
Stromacel Inc. has achieved several significant milestones in its successful journey. The company has developed groundbreaking technologies, paving the way for revolutionary advancements in the field. Stromacel Inc. has successfully launched innovative products, transforming the industry and strengthening its position as a market leader. With a relentless focus on research and development, the company has achieved remarkable breakthroughs that have garnered international recognition. Stromacel Inc. continuously strives to exceed expectations, offering unparalleled quality and service to its customers. These achievements have solidified Stromacel Inc.'s reputation as a forward-thinking company poised for continued growth and success.
Stromacel Inc is primarily present in the United States.
Stromacel Inc represents a core set of values and corporate philosophy that guide its operations. The company is committed to delivering exceptional products and services to its customers through innovation, integrity, and accountability. Stromacel Inc prioritizes customer satisfaction by constantly striving to exceed their expectations. With a strong focus on quality, the company aims to provide reliable solutions that enhance the overall customer experience. By fostering a culture of collaboration and continuous improvement, Stromacel Inc aims to build long-term relationships with its stakeholders and contribute positively to the communities it operates in.
Converted at the current exchange rate, the Stromacel share trades at 0.00 EUR (0.00 USD).
Stromacel Inc. is a leading company in the production of specialty papers and packaging solutions. The company was founded in 2005 and is headquartered in the state of Ohio, USA. Stromacel specializes in the development and production of paper products for various industries. The company offers a variety of specialty papers for a wide range of applications, including food packaging, medical packaging, labels, and various industrial film solutions. Stromacel specializes in the production of high-performance paper products. The company uses the latest technologies in the production of its products to ensure that its specialty papers meet customer requirements. Due to its high level of innovation and quality, Stromacel has built a broad customer base in various industries, including food, pharmaceutical, and automotive. Stromacel's production is divided into two main business areas: specialty papers and packaging solutions. The specialty papers division produces a variety of papers for different applications. Products include barrier layers for special applications, transfer papers for black and colored images, film laminating materials, and high-adhesive self-adhesive labels. Stromacel has perfected the technology for the production of high-quality specialty papers, including sustainable and recyclable materials. The packaging solutions division offers various types of packaging for different applications. The company specializes in the production of flexible packaging. The products are designed for use in the food industry, pharmaceutical and cosmetic industries, and household items. Examples of packaging solutions offered by Stromacel include reclosable packaging, stand-up pouches, and packaging for meat, vegetables, and fruits. The packaging solutions division meets customer requirements by providing customized solutions for a wide range of applications. Stromacel has also developed some target-specific applications to meet specific industry requirements. An example of this is the production of antimicrobial papers for use in the food and medical industries. These products are specially designed papers that have antimicrobial properties and are capable of preventing bacterial growth on the surface. Overall, Stromacel is a versatile company that offers a wide range of products and solutions for various industries. The company is constantly striving to develop new technologies and create innovative products to meet customer requirements. The company has built an excellent reputation in the industry and is known for its constant innovation and high product quality.
The revenue cannot currently be calculated for Stromacel.
The profit cannot currently be calculated for Stromacel.
The P/E ratio cannot be calculated for Stromacel at the moment.
The P/S cannot be calculated for Stromacel currently.
The Eulerpool Quality Score for Stromacel is 2/10.
The ISIN of Stromacel is US74371C2089. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Stromacel is A0Q8B7. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Stromacel is PROT. The ticker symbol is used to trade Stromacel shares on the stock exchange.
Stromacel paid dividends every year for the past 0 years.
Stromacel is assigned to the 'Health' sector.
The dividends of Stromacel are distributed in USD.
Stromacel stock
Stromacel Peer Group
Stromacel Ticker
Stromacel FIGI
All fundamentals and in-depth analysis of Stromacel
Our stock analysis for Stromacel stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Stromacel. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.